CONNECT WITH US
HealthTech

HealthTech

Malaria antibody protects infants but lowers immune response to R21 vaccine, trial finds

Medical Xpress logo

Published on

Add as a preferred source on Google
Malaria antibody protects infants but lowers immune response to R21 vaccine, trial finds

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A single intramuscular dose of an experimental malaria monoclonal antibody safely provided infants with strong protection during Mali's six-month malaria season. However, potential interference with the R21 malaria vaccine is putting plans to pursue development of L9LS for this age group on hold, according to results from a clinical trial presented at the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

The Phase Ib trial involved a monoclonal antibody known as L9LS that was developed by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The antibody has a strong track record of safety and efficacy in clinical trials involving older children in Mali and Kenya.

"We wanted to test L9LS in infants as young as 1 month old, because children are not eligible for malaria vaccination until they are at least 5 months old—and that leaves them especially vulnerable, particularly during times of intense malaria transmission," said Kassoum Kayentao, a physician-scientist at the University of Sciences, Techniques and Technologies in Bamako, Mali, which conducted the trial in partnership with NIAID colleagues.

"While protective efficacy against malaria infection was 78%, the monoclonal antibody also appeared to interfere with the immune response to subsequent immunization with the R21 malaria vaccine, which is widely used in Mali.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.